{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:46:43Z","timestamp":1760060803033,"version":"build-2065373602"},"reference-count":54,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Primary spinal cord tumors are rare neoplasms representing 2\u20134% of central nervous system tumors. Despite their low incidence, their impact on neurological function is profound. Historically, tumor classification and management have relied primarily on histopathology. However, advances in molecular diagnostics have highlighted the critical role of genetic alterations in tumor behavior, prognosis, and treatment response. This narrative review summarizes current evidence on genetic mutations in primary intramedullary spinal cord tumors, focusing on their prognostic value and implications for clinical management. Emphasis is placed on the integration of genetic features into diagnostic criteria and clinical practice, as distinct molecular profiles define many spinal cord tumor subtypes. Integration of molecular diagnostics into spinal cord tumor management represents a paradigm shift from morphology-based to biology-driven practice. Genetic alterations inform prognosis, refine risk stratification, and increasingly guide therapeutic decision-making, including the use of targeted therapies and adjuvant radiation. Despite progress, challenges remain due to the rarity of these tumors, small sample sizes, and limited access to molecular testing. Ultimately, molecular precision promises to enhance survival and quality of life for patients with these rare but impactful tumors.<\/jats:p>","DOI":"10.3390\/brainsci15101028","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T15:54:54Z","timestamp":1758642894000},"page":"1028","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic Markers and Mutations in Primary Spinal Cord Tumors and Their Impact on Clinical Management"],"prefix":"10.3390","volume":"15","author":[{"given":"Rouzbeh","family":"Motiei-Langroudi","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University of Kentucky, 780 Rose St., MS107A, Lexington, KY 40536, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dickman, C.A., Fehlings, M., and Gokaslan, Z.L. (2006). Spinal Cord and Spinal Column Tumors: Principles and Practice, Thieme.","DOI":"10.1055\/b-002-52051"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11910-011-0190-2","article-title":"Adult primary intradural spinal cord tumors: A review","volume":"11","author":"Chamberlain","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.14245\/ns.2244168.084","article-title":"Recent molecular and genetic findings in intramedullary spinal cord tumors","volume":"19","author":"Nagashima","year":"2022","journal-title":"Neurospine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15330338241262483","DOI":"10.1177\/15330338241262483","article-title":"Advances in molecular pathology, diagnosis and treatment of spinal cord astrocytomas","volume":"23","author":"Zhao","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 who classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/neuonc\/noab143","article-title":"DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology","volume":"23","author":"Pratt","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.wneu.2017.11.165","article-title":"Adult spinal ependymomas: An epidemiologic study","volume":"111","author":"Khalid","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wu, L., Wang, L., Zou, W., Yang, J., Jia, W., and Xu, Y. (2023). Primary spinal anaplastic ependymoma: A single-institute retrospective cohort and systematic review. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1083085"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11060-024-04623-4","article-title":"Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas","volume":"167","author":"Davison","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00401-019-02056-2","article-title":"MYCN amplification drives an aggressive form of spinal ependymoma","volume":"138","author":"Ghasemi","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jnen\/nlz064","article-title":"Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior","volume":"78","author":"Swanson","year":"2019","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/BRS.0000000000000889","article-title":"The molecular feature of hox gene family in the intramedullary spinal tumors","volume":"42","author":"Gu","year":"2017","journal-title":"Spine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00401-025-02866-7","article-title":"Strong nuclear expression of hoxb13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymoma","volume":"149","author":"Purkait","year":"2025","journal-title":"Acta Neuropathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.14245\/ns.2346388.194","article-title":"Spinal cord subependymoma: A subanalysis of the neurospinal society of japan\u2019s multicenter study of intramedullary spinal cord tumors","volume":"20","author":"Yagi","year":"2023","journal-title":"Neurospine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3171\/jns.1993.79.6.0867","article-title":"Central nervous system gangliogliomas. Part 2: Clinical outcome","volume":"79","author":"Lang","year":"1993","journal-title":"J. Neurosurg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14791\/btrt.2014.2.2.49","article-title":"Treatment and outcomes for gangliogliomas: A single-center review of 16 patients","volume":"2","author":"Song","year":"2014","journal-title":"Brain Tumor Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1005758313700","article-title":"Conservative surgery and radiotherapy in the treatment of spinal cord astrocytoma","volume":"33","author":"Jyothirmayi","year":"1997","journal-title":"J. Neurooncol."},{"key":"ref_18","first-page":"840","article-title":"Spinal intramedullary tumors","volume":"121","author":"Neyazi","year":"2024","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"iii48","DOI":"10.1093\/noajnl\/vdad166","article-title":"Astrocytomas of the spinal cord","volume":"6","author":"Tonn","year":"2024","journal-title":"Neuro Oncol. Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.14245\/ns.2346650.325","article-title":"Does h3k27m mutation impact survival outcome of high-grade spinal cord astrocytoma?","volume":"20","author":"Zhang","year":"2023","journal-title":"Neurospine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3171\/2021.2.SPINE201675","article-title":"A multicenter analysis of the prognostic value of histone h3 k27m mutation in adult high-grade spinal glioma","volume":"35","author":"Akinduro","year":"2021","journal-title":"J. Neurosurg. Spine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/s41379-019-0271-3","article-title":"Spinal cord high-grade infiltrating gliomas in adults: Clinico-pathological and molecular evaluation","volume":"32","author":"Alvi","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40478-020-00913-w","article-title":"The molecular characteristics of spinal cord gliomas with or without h3 k27m mutation","volume":"8","author":"Chai","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s40478-020-01078-2","article-title":"TERT promoter mutation confers favorable prognosis regardless of 1p\/19q status in adult diffuse gliomas with idh1\/2 mutations","volume":"8","author":"Arita","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gorria, T., Crous, C., Pineda, E., Hernandez, A., Domenech, M., Sanz, C., Jares, P., Mu\u00f1oz-M\u00e1rmol, A.M., Arp\u00ed-Lluc\u00eda, O., and Melendez, B. (2024). The c250t mutation of TERTp might grant a better prognosis to glioblastoma by exerting less biological effect on telomeres and chromosomes than the c228t mutation. Cancers, 16.","DOI":"10.3390\/cancers16040735"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10617","DOI":"10.18632\/oncotarget.3329","article-title":"TERT promoter mutations and telomere length in adult malignant gliomas and recurrences","volume":"6","author":"Heidenreich","year":"2015","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lee, Y., Park, C.K., and Park, S.H. (2024). Prognostic impact of TERT promoter mutations in adult-type diffuse gliomas based on who2021 criteria. Cancers, 16.","DOI":"10.3390\/cancers16112032"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liu, D.K., Wang, J., Guo, Y., Sun, Z.X., and Wang, G.H. (2019). Identification of differentially expressed genes and fusion genes associated with malignant progression of spinal cord gliomas by transcriptome analysis. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-50072-9"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101109","DOI":"10.1016\/j.inat.2021.101109","article-title":"Primary spinal glioblastoma multiforme. Single center experience and literature review","volume":"24","author":"Jokovic","year":"2021","journal-title":"Interdiscip. Neurosurg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"110862","DOI":"10.1016\/j.jocn.2024.110862","article-title":"Epidemiological and clinical characteristics of primary spinal cord glioblastomas: A systematic review and meta-analysis","volume":"130","author":"Lopes","year":"2024","journal-title":"J. Clin. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3171\/2024.4.SPINE231350","article-title":"Molecular profile and clinical outcome of adult primary spinal cord glioblastoma: A systematic review","volume":"41","author":"Ezzat","year":"2024","journal-title":"J. Neurosurg. Spine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/neuonc\/noaf041","article-title":"Local tumor control and neurological outcomes after surgery for spinal hemangioblastomas in sporadic and von hippel-lindau disease: A multicenter study","volume":"27","author":"Wach","year":"2025","journal-title":"Neuro Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cerretti, G., Pessina, F., Franceschi, E., Barresi, V., Salvalaggio, A., Padovan, M., Manara, R., Di Nunno, V., Bono, B.C., and Librizzi, G. (2023). Spinal ependymoma in adults: From molecular advances to new treatment perspectives. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1301179"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clineuro.2015.10.011","article-title":"Genetic and molecular distinctions in spinal ependymomas: A review","volume":"139","author":"Connolly","year":"2015","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e13068","DOI":"10.1111\/bpa.13068","article-title":"Updates in the classification of ependymal neoplasms: The 2021 who classification and beyond","volume":"32","author":"Kresbach","year":"2022","journal-title":"Brain Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40478-020-00973-y","article-title":"High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma","volume":"8","author":"Raffeld","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1215\/S1152851704001231","article-title":"High failure rate in spinal ependymomas with long-term follow-up","volume":"7","author":"Gomez","year":"2005","journal-title":"Neuro Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.humpath.2018.10.011","article-title":"Detection of h3k27m mutation in cases of brain stem subependymoma","volume":"84","author":"Yao","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00401-021-02300-8","article-title":"TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma","volume":"141","author":"Thomas","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.humpath.2015.09.041","article-title":"Intramedullary gangliogliomas: Histopathologic and molecular features of 25 cases","volume":"49","author":"Gessi","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Di Nunno, V., Gatto, L., Tosoni, A., Bartolini, S., and Franceschi, E. (2022). Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1067252"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Garnier, L., Ducray, F., Verlut, C., Mihai, M.I., Cattin, F., Petit, A., and Curtit, E. (2019). Prolonged response induced by single agent vemurafenib in a BRAF V600E spinal ganglioglioma: A case report and review of the literature. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00177"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1497","DOI":"10.1212\/WNL.0000000000206834","article-title":"Natural course and prognosis of primary spinal glioblastoma: A nationwide study","volume":"100","author":"Amelot","year":"2023","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Liu, A., Hou, C., Chen, H., Zong, X., and Zong, P. (2016). Genetics and epigenetics of glioblastoma: Applications and overall incidence of idh1 mutation. Front. Oncol., 6.","DOI":"10.3389\/fonc.2016.00016"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Li, Q., Aishwarya, S., Li, J.P., Pan, D.X., and Shi, J.P. (2022). Gene expression profiling of glioblastoma to recognize potential biomarker candidates. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.832742"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s00381-020-04712-5","article-title":"Hemangioblastoma and von hippel-lindau disease: Genetic background, spectrum of disease, and neurosurgical treatment","volume":"36","author":"Klingler","year":"2020","journal-title":"Childs Nerv. Syst."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Degirmenci, U., Wang, M., and Hu, J. (2020). Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy. Cells, 9.","DOI":"10.3390\/cells9010198"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"eaau5935","DOI":"10.1126\/sciadv.aau5935","article-title":"Multiple modes of prc2 inhibition elicit global chromatin alterations in h3k27m pediatric glioma","volume":"4","author":"Stafford","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/pro.3647","article-title":"Polycomb repressive 2 complex-molecular mechanisms of function","volume":"28","author":"Kouznetsova","year":"2019","journal-title":"Protein Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Alohali, S., Payne, A.E., Pusztaszeri, M., Rajab, M., Forest, V.I., Hier, M.P., Tamilia, M., and Payne, R.J. (2023). Effect of having concurrent mutations on the degree of aggressiveness in patients with thyroid cancer positive for TERT promoter mutations. Cancers, 15.","DOI":"10.3390\/cancers15020413"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","article-title":"New brain tumor entities emerge from molecular classification of CNS-PNETS","volume":"164","author":"Sturm","year":"2016","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00401-015-1519-8","article-title":"Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets","volume":"131","author":"Sahm","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/10\/1028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:48:21Z","timestamp":1760035701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/10\/1028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["brainsci15101028"],"URL":"https:\/\/doi.org\/10.3390\/brainsci15101028","relation":{},"ISSN":["2076-3425"],"issn-type":[{"type":"electronic","value":"2076-3425"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}